Orphan Drug Designations are crucial for the development of treatments for rare diseases, offering benefits such as regulatory support and market exclusivity upon approval. For Edgewise Therapeutics, this designation likely enhances the commercial prospects of Sevasemten in Europe, potentially leading to increased investor interest and a positive impact on the stock price in the short term.